Top Page
Dr Reddy's Laboratories
(NYSE:RDY)
Dr Reddy's Laboratories (RDY) vs. SPDR S&P 500 ETF (SPY)
Dr Reddy's Laboratories Business Overview & Revenue Model
Dr Reddy's Laboratories Earnings Call Summary
Dr Reddy's Laboratories Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 860.40B | 325.54B | 279.16B | 245.88B | 214.39B | 2.56B |
| Gross Profit | 482.44B | 190.43B | 163.61B | 139.34B | 113.84B | 1.30B |
| EBITDA | 245.60B | 96.67B | 88.42B | 74.43B | 45.08B | 534.77M |
| Net Income | 145.99B | 56.54B | 55.68B | 45.07B | 23.57B | 232.21M |
Balance Sheet | ||||||
| Total Assets | 542.00B | 492.99B | 387.52B | 321.85B | 292.83B | 3.63B |
| Cash, Cash Equivalents and Short-Term Investments | 69.81B | 57.91B | 81.47B | 61.80B | 44.37B | 472.87M |
| Total Debt | 58.54B | 46.77B | 20.02B | 13.47B | 33.84B | 414.53M |
| Total Liabilities | 179.92B | 155.82B | 106.97B | 90.86B | 102.30B | 1.26B |
| Stockholders Equity | 358.49B | 333.39B | 280.55B | 230.99B | 190.53B | 2.37B |
Cash Flow | ||||||
| Free Cash Flow | 47.82B | 12.03B | 18.00B | 40.01B | 9.06B | 23.14B |
| Operating Cash Flow | 148.78B | 46.43B | 45.43B | 58.88B | 28.11B | 35.70B |
| Investing Cash Flow | -114.07B | -58.08B | -40.28B | -41.37B | -26.39B | -22.66B |
| Financing Cash Flow | -37.26B | 18.91B | -3.76B | -26.86B | -2.42B | -298.00M |
Dr Reddy's Laboratories Technical Analysis
Dr Reddy's Laboratories Risk Analysis
Dr Reddy's Laboratories Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $13.49B | 31.85 | 14.96% | ― | 19.61% | 11.36% | |
73 Outperform | $10.95B | 16.28 | 17.72% | 0.64% | 10.63% | 6.35% | |
60 Neutral | $15.15B | -4.14 | -21.09% | 3.99% | -6.40% | -320.23% | |
60 Neutral | $37.22B | 52.83 | 10.77% | ― | -0.25% | ― | |
58 Neutral | $4.17B | 928.87 | ― | ― | 9.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $2.05B | -40.27 | -0.65% | 8.48% | -2.55% | 66.00% |
Dr Reddy's Laboratories Corporate Events
On January 10, 2026, Dr. Reddy’s Laboratories disclosed that, following a pre-approval inspection by the U.S. Food and Drug Administration (USFDA) at its biologics manufacturing facility in Bachupally, Hyderabad conducted in relation to a product application referenced in an earlier communication on September 13, 2025, the company has now received a Post-Application Action Letter (PAAL) from the USFDA concerning its submitted response. The drugmaker said it will work closely with the US regulator and is committed to addressing the queries raised in the PAAL, indicating that timelines for approval of the related biologic product could depend on how swiftly and satisfactorily these issues are resolved, an outcome that may influence its near-term US biologics pipeline and regulatory risk profile for investors and other stakeholders.
The most recent analyst rating on (RDY) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On January 8, 2026, Dr. Reddy’s Laboratories announced that it will release its financial results for the quarter and nine months ended December 31, 2025 (Q3 FY26) on Wednesday, January 21, 2026, following a meeting of its board of directors. The company will also hold an earnings call on January 21, 2026 at 19:30 IST / 9:00 ET, with related materials including a press presentation, call audio and transcript to be made available via stock exchanges and the company’s website, providing investors and other stakeholders structured access to management’s discussion of recent financial performance.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On January 1, 2026, Dr. Reddy’s Laboratories disclosed that it has received five separate orders from the Goods and Services Tax (GST) Authority, specifically from the Joint Commissioner in the Office of the Principal Commissioner of Central Tax, Visakhapatnam, covering financial years 2018-19 to 2022-23. The orders, dated and received on December 31, 2025, allege that the company availed excess input tax credit under the APGST Act 2017 and impose penalties totaling several hundred million rupees across the five years. Dr. Reddy’s stated that, based on its evaluation, the demands and penalties are not expected to have a material impact on its financials, operations or other activities, and the company is considering filing an appeal with the appellate authority, signaling a potential tax dispute but limited immediate operational or balance sheet risk for stakeholders.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On December 31, 2025, Dr. Reddy’s Laboratories disclosed that its wholly owned Swiss subsidiary received a Complete Response Letter from the U.S. Food and Drug Administration for the Biologics License Application for AVT03 (denosumab), a proposed biosimilar to Prolia and Xgeva developed by Alvotech. The FDA’s response is tied to observations from a pre-license inspection of Alvotech’s manufacturing facility in Reykjavik, signaling that approval of this important biosimilar candidate for the U.S. market will be delayed until the inspection issues are resolved, potentially impacting the timing of Dr. Reddy’s entry into the denosumab biosimilar space and related revenue expectations.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On December 23, 2025, Dr. Reddy’s Laboratories announced that its Board of Directors will meet on January 21, 2026 to consider and approve the company’s unaudited standalone and consolidated financial results for the quarter ended December 31, 2025. In line with securities regulations on insider trading, the company also disclosed that its trading window for dealing in its securities will be closed from December 25, 2025 to January 23, 2026, temporarily restricting trades by designated persons ahead of the quarterly earnings announcement and underscoring its compliance focus for investors across its Indian and U.S. listings.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Dr. Reddy’s Laboratories announced its participation in an investor conference organized by Investec on December 22, 2025, in Chennai. This engagement reflects the company’s ongoing efforts to maintain transparency and strengthen relationships with institutional investors, potentially impacting its market perception and investor confidence.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On December 12, 2025, Dr. Reddy’s Laboratories announced that the United States Food & Drug Administration (USFDA) completed a Good Manufacturing Practice (GMP) and Pre-Approval Inspection (PAI) at its formulations facility in Srikakulam, Andhra Pradesh. The inspection, conducted from December 4 to December 12, resulted in a Form 483 with five observations, which the company plans to address within the stipulated timeline. This inspection and its outcomes are crucial for the company’s compliance and operational integrity, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On December 9, 2025, Dr. Reddy’s Laboratories announced the allotment of 9,165 equity shares to eligible employees under its Employee Stock Options Schemes of 2002 and 2007. This move is part of the company’s ongoing efforts to reward and retain its workforce, potentially enhancing employee satisfaction and motivation. The issuance of these shares, which are fully paid up and rank pari passu with existing shares, reflects the company’s commitment to its employee benefits programs and could positively impact its operational dynamics and stakeholder relations.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On December 8, 2025, Dr. Reddy’s Laboratories announced a strategic collaboration and exclusive licensing agreement with Immutep SAS to develop and commercialize Eftilagimod Alfa, a novel cancer immunotherapy, outside North America, Europe, Japan, and Greater China. This agreement allows Dr. Reddy’s to expand its oncology portfolio by leveraging its market access and expertise to advance Eftilagimod Alfa’s development, while Immutep will receive an upfront payment of USD 20 million and potential milestone payments. The collaboration underscores Dr. Reddy’s commitment to delivering innovative cancer treatments and positions the company to enhance its impact in global oncology markets.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Dr. Reddy’s Laboratories announced its participation in an investor conference organized by Bank of America in Singapore on December 8-9, 2025. This engagement is part of the company’s ongoing efforts to maintain transparency and communication with its investors, potentially impacting its market perception and stakeholder relations.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On November 28, 2025, Dr. Reddy’s Laboratories announced its participation in an upcoming investor conference organized by Nomura in Tokyo, Japan, scheduled for December 4-5, 2025. This engagement underscores the company’s proactive approach in maintaining transparency and fostering relationships with institutional investors, potentially impacting its market perception and stakeholder confidence.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Dr. Reddy’s Laboratories announced on November 24, 2025, that it has received European Commission approval for AVT03, a biosimilar of Prolia® and Xgeva®, which are used to treat osteoporosis and prevent bone complications in cancer patients. This approval, based on comprehensive evidence and clinical trials, allows Dr. Reddy’s to market AVT03 across EU and EEA countries, enhancing its position in the biosimilars market and potentially increasing its market share in Europe and the US, where it holds exclusive commercialization rights.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Dr. Reddy’s Laboratories announced its participation in several investor conferences scheduled for late November 2025. These meetings, organized by Investec, Citi, and HSBC, will take place in Mumbai, Hyderabad, and Hong Kong, respectively, and involve in-person group meetings with institutional investors. The participation in these conferences underscores Dr. Reddy’s commitment to engaging with investors and providing updates on its strategic initiatives, potentially impacting its market perception and investor relations.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On November 17, 2025, Dr. Reddy’s Laboratories announced its participation in an investor conference organized by JM Financial, scheduled for November 21, 2025, in Mumbai. This meeting, which will be conducted in person, aims to engage with investor groups and provide insights into the company’s operations and strategies. The event is significant for stakeholders as it reflects the company’s proactive approach in maintaining transparency and fostering investor relations.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On November 14, 2025, Dr. Reddy’s Laboratories announced that the United States Food & Drug Administration (USFDA) completed a Good Manufacturing Practice (GMP) inspection at their API facility in Srikakulam, Andhra Pradesh, with zero observations. This successful inspection underscores the company’s commitment to maintaining high-quality standards in its manufacturing processes, potentially strengthening its position in the global pharmaceutical market.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On November 13, 2025, Dr. Reddy’s Laboratories announced the allotment of 7,430 equity shares to eligible employees under its Employees Stock Options Scheme, 2002. This move reflects the company’s commitment to employee engagement and retention, potentially enhancing its operational efficiency and stakeholder value.
The most recent analyst rating on (RDY) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Dr. Reddy’s Laboratories announced the resignation of Mr. Jayanth Sridhar, the Global Head of Biologics, effective January 31, 2026. This change in senior management is part of the company’s ongoing adjustments to its leadership team, which could impact its strategic direction in the biologics sector.
The most recent analyst rating on (RDY) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On October 29, 2025, Dr. Reddy’s Laboratories received a Notice of Non-Compliance from the Pharmaceutical Drugs Directorate in Canada concerning their Abbreviated New Drug Submission for Semaglutide Injection. The notice requests additional information and clarifications, which the company plans to address promptly. Despite this setback, Dr. Reddy’s remains confident in the quality and safety of their product and is committed to making it available in Canada and other markets as soon as possible. The company appreciates the support of its stakeholders and will provide further updates when appropriate.
The most recent analyst rating on (RDY) stock is a Buy with a $16.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On October 25, 2025, Dr. Reddy’s Laboratories announced the availability of audio recordings from their earnings call conducted on October 24, 2025. This call covered the financial results for the quarter ending September 30, 2025. The release of these recordings is part of the company’s commitment to transparency and regulatory compliance, providing stakeholders with insights into their financial performance and strategic direction.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On October 25, 2025, Dr. Reddy’s Laboratories announced the publication of its unaudited financial results for the quarter and half-year ending September 30, 2025. These results were advertised in the Financial Express and Andhra Prabha newspapers. This disclosure is part of the company’s compliance with the Securities and Exchange Board of India’s regulations, reflecting its commitment to transparency and providing stakeholders with timely financial information.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Dr. Reddy’s Laboratories has released its unaudited financial results for the second quarter and half-year ending September 30, 2025. This announcement, made on October 24, 2025, provides stakeholders with insights into the company’s financial performance during this period, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Dr. Reddy’s Laboratories announced on October 24, 2025, that Mr. Sanjay Sharma, the Global Head of Operations, will take on additional responsibilities as the Chief Human Resources Officer (CHRO) effective December 1, 2025. This decision follows the resignation of Ms. Archana Bhaskar, the current CHRO, effective November 30, 2025. Mr. Sharma, with extensive experience in the FMCG and Pharmaceuticals industry, is expected to bring significant expertise to his expanded role, potentially impacting the company’s strategic direction and operational efficiency.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
On October 24, 2025, Dr. Reddy’s Laboratories announced the approval of its unaudited financial results for the quarter and half-year ending September 30, 2025, during a board meeting. The results were prepared in compliance with both International Financial Reporting Standards and Indian Accounting Standards. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Dr. Reddy’s Laboratories has released its quarterly report for the period ending September 30, 2025, indicating a stable financial position with no material modifications required for its interim financial statements. The report highlights the company’s adherence to International Accounting Standards and its continued focus on expanding its generic medicines business despite challenges such as price erosion and regulatory hurdles. The review by Ernst & Young Associates LLP confirms the reliability of the financial data presented, reinforcing stakeholder confidence in the company’s financial health and operational strategies.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Dr. Reddy’s Laboratories announced that it will release its financial results for the quarter and six months ending September 30, 2025, on October 24, 2025, following a board meeting. An earnings call is scheduled for the same day at 19:30 PM IST / 10:00 AM ET to discuss the company’s financial performance. This announcement is significant for stakeholders as it provides insights into the company’s recent financial health and strategic direction.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.